Harold Preiksaitis, MD
Gastroenterology · Spokane, WANPI 1962495283
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,400 of the $49,972 with a category attached, or 70.8%. Phathom Pharmaceuticals, Inc. accounts for 81.9% of it on its own, with 24 other manufacturers making up the rest. Among gastroenterology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 323 payments — averaging $154.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$41K
- Pfizer$4K
- AbbVie$1K
- Johnson & Johnson$601
- Regeneron Healthcare Solutions, Inc.$526
- Takeda Pharmaceuticals U.S.A., Inc.$515
- plus $3K from 19 others
Across 190 payments — averaging $5270.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$237K
- Modernatx, Inc.$157K
- Boehringer Ingelheim$113K
- Bristol Myers Squibb$106K
- Janssen Research & Development, LLC$83K
- Takeda Pharmaceuticals U.S.A., Inc.$79K
- plus $226K from 11 others
What the payments were for
- Consulting fees$3,0006%
- Speaking & faculty fees$35,40071%
- Travel & lodging$3,8528%
- Food & beverage$7,60015%
- Education$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 43 | $40,910 |
| Pfizer | 33 | $3,640 |
| AbbVie | 75 | $1,119 |
| Johnson & Johnson | 33 | $601 |
| Regeneron Healthcare Solutions, Inc. | 18 | $526 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $515 |
| E.r. Squibb & Sons, L.L.C. | 3 | $381 |
| Boston Scientific | 10 | $377 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $349 |
| Lilly USA, LLC | 9 | $269 |
| Gilead | 6 | $249 |
| Novo Nordisk | 6 | $164 |
| Ardelyx, Inc. | 8 | $163 |
| Dova Pharmaceuticals | 1 | $115 |
| Merck | 8 | $114 |
| Intercept Pharmaceuticals, Inc. | 4 | $86 |
| Braintree Laboratories, Inc. | 4 | $66 |
| Janssen Scientific Affairs, LLC | 1 | $64 |
| Bristol Myers Squibb | 4 | $63 |
| Sanofi | 3 | $53 |
| Ironwood Pharmaceuticals, Inc | 2 | $39 |
| Fresenius Kabi USA, LLC | 2 | $33 |
| UCB, Inc. | 2 | $32 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Amgen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,972 in reported general payments places this provider in the 95th percentile of 447 gastroenterology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf)Adalimumab | 13 | $160,108 |
| RinvoqUpadacitinib | 12 | $91,266 |
| Humira PenAdalimumab | 12 | $81,484 |
| LinzessLinaclotide | 11 | $7,254 |
| Budesonide DrBudesonide | 17 | $2,648 |
| Lactated RingersRinger's Solution,lactated | 50 | $2,245 |
| Famotidine | 133 | $1,184 |
| Pantoprazole Sodium | 163 | $1,153 |
| Omeprazole | 71 | $1,097 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 50 | $802 |
| Ondansetron OdtOndansetron | 89 | $671 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $626 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 32 | $531 |
| Dicyclomine Hcl | 28 | $409 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 20 | $311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Rinvoq, Linzess | $1,119 | $258,62736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 447 gastroenterology providers in Washington.
Other gastroenterology in Spokane
- Eashen LiuSpokane$62K
- Michael KestellSpokane$22K
- Miguel Ordonez CastellanosSpokane$16K
- Nicolas Villa GuillenSpokane$15K
- Michael ChioreanIssaquah$1.4M
- Kris KowdleySeattle$1.4M
- Venkatachala MohanBellevue$564K
- Scott LeeSeattle$220K
- John SunTacoma$219K
- Klaus MergenerEdmonds$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.